Neurofibromatosis 1 has a germ line mutation in the NF1 tumor suppression gene.
On physical examination, there was a firm irregular mass in the left upper neck, 3 cm x 3 cm in size with multiple lobulations involving the sternocleidomastoid muscle with normal overlying skin. No café-au-lait spots were noticed. Head was normocephalic with soft anterior fontanel. The left ear appeared larger, and the right ear had a fold in the ear lobe. Neurologically, the baby had spontaneous movement, tone was diminished bilaterally, and suck was present but poor. Fifth toes were over-riding bilaterally. He was having positional desaturation and was intubated. He was subsequently extubated and was put on oxygen via nasal cannula and continuous positive airway pressure.
Magnetic resonance imaging (MRI) of the head (figure 1) demonstrated a mass involving the left cavernous sinus and spreading to the left orbital region. There was hemorrhage noted in the periventricular white matter of left lateral ventricle extending from body to the posterior horn. MRI of the neck (figure 2) was positive for extensive adenopathy, left more than right, with extension into the deep face region and infratemporal fossa on the left side. The left internal carotid artery was displaced laterally and was narrowed throughout its course in the neck to the skull base. MRI of the chest, abdomen, and pelvis (figure 3) demonstrated a mass extending from the mediastinum to the left pelvic retroperitoneal region, including the mesenteric vasculature and spinal canal at multiple levels with compression of the spinal cord.
Karyotype was normal 46 XY. Pathology obtained from the left deep neck mass confirmed plexiform neurofibroma (figure 4). NF1 genetic testing was positive. Due to the extensive nature of the tumor in our neonate, surgery was not a viable option. The baby died after 3 weeks of conservative management.
Discussion
Plexiform neurofibromas arise from multiple nerve fascicles. They tend to grow along the length of nerve and extend into surrounding structures including skin, fascia, muscle, bone, and internal organs. Histologically, plexiform neurofibromas are characterized by an increase in the endoneurial matrix and proliferation of Schwann cells. 5 Most plexiform neurofibromas are diagnosed in childhood, based on the National Institute of Health (NIH) diagnostic criteria. 6 The NIH diagnostic criteria is highly sensitive and specific for the adult population, but only about half the children with NF1 and an unknown family history meet the NIH criteria by 1 year of age. 7 This makes the diagnosis of neurofibroma more challenging in a patient like ours. There are only a few reports in the literature of plexiform neurofibromas in the neonatal period. Mersal et al 8 reported a 15-day-old neonate with a neck mass, causing airway and esophageal obstruction. Unlike our case, the baby also had café-au-lait spots. MRI revealed extension of the neck mass into the skull base and floor of the middle cranial fossa. Biopsy confirmed plexiform neurofibroma. The baby was managed with partial decompression of the tumor. 8 Our case, however, was different because our patient was a premature neonate with severe extension of the tumor with impingement on the vital structures including the brain, spinal cord, airways, and blood vessels. We conducted a careful literature search and did not find any reports of a premature neonate with an extensive plexiform neurofibroma.
Waggoner et al 9 did one of the largest retrospective studies of plexiform neurofibroma patients and their symptoms, in which they studied 68 NF1 patients with plexiform neurofibroma. They reported six patients with plexiform neurofibroma at birth and three patients with plexiform neurofibroma between birth and 6 months of age. In about 44%, the tumor was localized to trunk, 38% to limbs, and 18% head and neck. No extensive tumor, as found in our patient, was reported from the cohort. Most patients in the cohort were managed surgically (53%), with the most common reason for performing surgery being medical complications related to the tumor. 9 Prenatal ultrasound in our patient at 32 weeks of gestation was reported normal. To our knowledge, diagnosis of the plexiform neurofibroma through prenatal ultrasound has not been previously reported. There have been few case reports with an abnormal perinatal ultrasound that revealed polyhydramnios, macrocephaly, and hydrocephalus; 10 however, because of the nonspecific nature of the findings, prenatal diagnosis of plexiform neurofibromas via ultrasound is not possible. Although MRI is the imaging modality of choice in the postnatal period, the typical hyperintense MR lesions have not been demonstrated prenatally because of immature myelination. 6 There is no specific treatment guideline for plexiform neurofibromas. They are highly refractory to radiotherapy and chemotherapy because of the slow growing nature of the tumor. 11 In a phase II trial of imatinib mesylate for plexiform neurofibromas in patients aged 3 to 52 years (median age 11 years), 23 patients received imatinib mesylate for at least 6 months; 6 patients (26%, 95% CI 10-48) had a 20% or more decrease in the volume of one or more plexiform tumors, with a maximum of 38% reported in one of the tumors. 12 In our case, imatinib was not ideal, because the tumor was negative for c-kit. A Phase II trial of sirolimus, which blocks the activity of a protein mTOR involved in cell growth, has been recently completed. Other clinical trials that include chemotherapeutic drugs, anti-angiogenesis drugs, and drugs that modulate the presumed genetic underpinnings are underway. 13 Surgery still remains the main stay of treatment.
14 However, surgical management is very challenging due to the diffuse infiltrative nature of the disease that impedes complete surgical resection. There is a high rate of tumor regrowth and a high risk of neurological deficit after tumor resection. In a retrospective review conducted at Children's Hospital of Philadelphia, of 121 patients who underwent resection, only 54% were free of tumor recurrence at the 10 year follow up.
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The indications for surgical intervention include cosmesis, Extensive Plexiform Neurofibroma in a Neonate intractable pain, neurological deficit, suspected malignant transformation, and compressive symptoms. 15 Surgery was not an option because of the extensive nature of the disease that involved vital structures including the internal carotid and celiac arteries with impingement of the airway, spinal cord, and extension into brain in this premature neonate. This is the first case of an extensive plexiform neurofibroma to be reported in a premature neonate. Family history was negative for neurofibromatosis, therefore it is possible that this was a de novo mutation. Antenatal ultrasound was not effective for diagnosing plexiform neurofibromas and surgical resection was not possible. The clinical trials for medical management have not been promising so far. Therefore, alternative treatment is needed to improve outcome.
